VLT-015

CF Pharma, LLC · Phase 1 active Small molecule

At a glance

Generic name	VLT-015
Also known as	FAP-2015
Sponsor	CF Pharma, LLC
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

VLT-015 in Patients With Schizophrenia (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VLT-015 CI brief — competitive landscape report
VLT-015 updates RSS · CI watch RSS
CF Pharma, LLC portfolio CI